Cargando…
Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
OBJECTIVE: The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat indivi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806069/ https://www.ncbi.nlm.nih.gov/pubmed/36581417 http://dx.doi.org/10.1136/bmjopen-2022-066846 |
_version_ | 1784862454925230080 |
---|---|
author | Kravchenko, Olga V Boyce, Richard D Gomez-Lumbreras, Ainhoa Kocis, Paul T Villa Zapata, Lorenzo Tan, Malinda Leonard, Charles E Andersen, Kathleen M Mehta, Hemalkumar Alexander, G Caleb Malone, Daniel C |
author_facet | Kravchenko, Olga V Boyce, Richard D Gomez-Lumbreras, Ainhoa Kocis, Paul T Villa Zapata, Lorenzo Tan, Malinda Leonard, Charles E Andersen, Kathleen M Mehta, Hemalkumar Alexander, G Caleb Malone, Daniel C |
author_sort | Kravchenko, Olga V |
collection | PubMed |
description | OBJECTIVE: The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE. DESIGN: We used nested case–control study design. SETTING: This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repository for COVID-19 in the USA. PARTICIPANTS: Study participants were adults over 18 years who were exposed to a DOAC for 10 or more consecutive days. Exposure to dexamethasone was at least 5 or more consecutive days. PRIMARY AND SECONDARY OUTCOME MEASURES: Our primary exposure variable was concomitant exposure to dexamethasone for 5 or more days after exposure to either rivaroxaban or apixaban for 5 or more consecutive days. We used McNemar’s Χ(2) test and adjusted logistic regression to evaluate association between concomitant use of dexamethasone with either apixaban or rivaroxaban. RESULTS: McNemar’s Χ(2) test did not find a discernible association of TEE in patients concomitantly exposed to dexamethasone and a DOAC (χ(2)=0.5, df=1, p=0.48). In addition, a conditional logistic regression model did not find an increase in the risk of TEE (adjusted OR 1.15, 95% CI 0.32 to 4.18). CONCLUSION: This nested case–control study did not find evidence of an association between concomitant exposure to dexamethasone and a DOAC with an increase in risk of TEE. Due to small sample size, an association cannot be completely ruled out. |
format | Online Article Text |
id | pubmed-9806069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-98060692023-01-03 Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) Kravchenko, Olga V Boyce, Richard D Gomez-Lumbreras, Ainhoa Kocis, Paul T Villa Zapata, Lorenzo Tan, Malinda Leonard, Charles E Andersen, Kathleen M Mehta, Hemalkumar Alexander, G Caleb Malone, Daniel C BMJ Open Pharmacology and Therapeutics OBJECTIVE: The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE. DESIGN: We used nested case–control study design. SETTING: This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repository for COVID-19 in the USA. PARTICIPANTS: Study participants were adults over 18 years who were exposed to a DOAC for 10 or more consecutive days. Exposure to dexamethasone was at least 5 or more consecutive days. PRIMARY AND SECONDARY OUTCOME MEASURES: Our primary exposure variable was concomitant exposure to dexamethasone for 5 or more days after exposure to either rivaroxaban or apixaban for 5 or more consecutive days. We used McNemar’s Χ(2) test and adjusted logistic regression to evaluate association between concomitant use of dexamethasone with either apixaban or rivaroxaban. RESULTS: McNemar’s Χ(2) test did not find a discernible association of TEE in patients concomitantly exposed to dexamethasone and a DOAC (χ(2)=0.5, df=1, p=0.48). In addition, a conditional logistic regression model did not find an increase in the risk of TEE (adjusted OR 1.15, 95% CI 0.32 to 4.18). CONCLUSION: This nested case–control study did not find evidence of an association between concomitant exposure to dexamethasone and a DOAC with an increase in risk of TEE. Due to small sample size, an association cannot be completely ruled out. BMJ Publishing Group 2022-12-29 /pmc/articles/PMC9806069/ /pubmed/36581417 http://dx.doi.org/10.1136/bmjopen-2022-066846 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Pharmacology and Therapeutics Kravchenko, Olga V Boyce, Richard D Gomez-Lumbreras, Ainhoa Kocis, Paul T Villa Zapata, Lorenzo Tan, Malinda Leonard, Charles E Andersen, Kathleen M Mehta, Hemalkumar Alexander, G Caleb Malone, Daniel C Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) |
title | Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) |
title_full | Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) |
title_fullStr | Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) |
title_full_unstemmed | Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) |
title_short | Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) |
title_sort | drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the national covid cohort collaborative (n3c) |
topic | Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806069/ https://www.ncbi.nlm.nih.gov/pubmed/36581417 http://dx.doi.org/10.1136/bmjopen-2022-066846 |
work_keys_str_mv | AT kravchenkoolgav drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT boycerichardd drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT gomezlumbrerasainhoa drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT kocispault drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT villazapatalorenzo drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT tanmalinda drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT leonardcharlese drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT andersenkathleenm drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT mehtahemalkumar drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT alexandergcaleb drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c AT malonedanielc drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c |